KW
GILD icon

Keyvantage Wealth’s Gilead Sciences GILD Stock Holding History

Keyvantage Wealth’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$689K Sell
5,453
-373
-6% -$49.1K 0.26% 48
2026
Q1 		$812K Buy
5,826
+554
+11% +$77.6K 0.36% 43
2025
Q4 		$647K Sell
5,272
-49
-0.9% -$5.96K 0.28% 54
2025
Q3 		$591K Sell
5,321
-240
-4% -$27.3K 0.25% 55
2025
Q2 		$617K Sell
5,561
-75
-1% -$7.98K 0.28% 51
2025
Q1 		$631K Sell
5,636
-884
-14% -$91.2K 0.31% 48
2024
Q4 		$602K Buy
+6,520
New +$587K 0.43% 40

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Keyvantage Wealth's GILD Position: Q2 2026 in Review

Keyvantage Wealth reduced its Gilead Sciences (GILD) stake by 6.4% in Q2 2026, selling an estimated $49.1K and leaving 5,453 shares worth $689K. The position accounts for 0.26% of the portfolio, ranked #48.

Keyvantage Wealth first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $812K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Keyvantage Wealth held 5,453 shares of Gilead Sciences worth $689K as of Q2 2026.
  • Keyvantage Wealth sold 373 Gilead Sciences shares in Q2 2026, an estimated $49.1K.
  • Gilead Sciences made up 0.26% of Keyvantage Wealth's portfolio in Q2 2026, its #48 holding.
  • Keyvantage Wealth first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • Keyvantage Wealth's Gilead Sciences position peaked at $812K in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Keyvantage Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.